The shares of World Wrestling Entertainment Inc. (NYSE:WWE) has been pegged with a rating of Neutral by JP Morgan in its latest research note that was published on February 11, 2020. The Services company has also assigned a $47 price target. JP Morgan wasn’t the only research firm that published a report of World Wrestling Entertainment Inc., with other equities research analysts also giving their opinion on the stock. Wells Fargo advised investors in its research note published on February 10, 2020, to Underweight the WWE stock while also putting a $36 price target. The stock had earned Peer Perform rating from Wolfe Research Markets when it published its report on February 07, 2020. The stock was given Equal-Weight rating by Morgan Stanley in its report released on January 31, 2020, the day when the price target on the stock was placed at 54. Loop Capital was of a view that WWE is Hold in its latest report on January 31, 2020. Evercore ISI thinks that WWE is worth In-line rating. This was contained in the firm’s report on January 31, 2020 in which the stock’s price target was also moved to 50.
Amongst the analysts that rated the stock, 1 have recommended investors to sell it, 7 believe it has the potential for further growth, thus rating it as Hold while 8 advised investors to purchase the stock. The consensus currently stands at a Overweight while its average price target is $53.33. The price of the stock the last time has raised by 8.75% from its 52-Week high price while it is -56.44% than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 30.06.
The shares of the company added by 3.60% during the trading session on Thursday, reaching a low of $42.20 while ending the day at $43.76. During the trading session, a total of 2.24 million shares were traded which represents a -23.02% decline from the average session volume which is 1.82 million shares. WWE had ended its last session trading at $42.24. World Wrestling Entertainment Inc. currently has a market cap of $3.6 billion, while its P/E ratio stands at 51.12, while its P/E earnings growth sits at 1.59, with a beta of 1.14. World Wrestling Entertainment Inc. debt-to-equity ratio currently stands at 2.03, while its quick ratio hovers at 1.20 WWE 52-week low price stands at $40.24 while its 52-week high price is $100.45.
The company in its last quarterly report recorded $0.78 earnings per share which is above the predicted by most analysts. The World Wrestling Entertainment Inc. generated 90.45 million in revenue during the last quarter. In the second quarter last year, the firm recorded $0.06 earnings per share. Compared to the same quarter last year, the firm’s revenue was up by 114.1%. World Wrestling Entertainment Inc. has the potential to record 1.56 EPS for the current fiscal year, according to equities analysts.
Investment analysts at Evercore ISI published a research note on February 03, 2020 where it informed investors and clients that CRISPR Therapeutics AG (NASDAQ:CRSP) is now rated as In-line. Their price target on the stock stands at $52. Even though the stock has been trading at $57.75/share, analysts expect it to surge by 0.64% to reach $74.96/share. It started the day trading at $61.11 and traded between $56.54 and $58.12 throughout the trading session.
A look at its technical shows that CRSP’s 50-day SMA is 61.08 while its 200-day SMA stands at 49.90. The stock has a high of $74.00 for the year while the low is $30.53. The stock, however, witnessed a rise in its short on 01/31/20. Compared to previous close which recorded 3.28 M shorted shares, the short percentage went lower by -5.78%, as 3.09M WWE shares were shorted. At the moment, only 6.91% of CRISPR Therapeutics AG shares were sold short. The company’s average trading volume currently stands at 1.25M shares, which means that the short-interest ratio is just 2.63 days. Over the past seven days, the company moved, with its shift of 6.98%. Looking further, the stock has raised 8.47% over the past 90 days while it gained 25.61% over the last six months.
The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. The Nikko Asset Management Americas, … bought more CRSP shares, increasing its portfolio by 9.80% during the last quarter. This move now sees The Nikko Asset Management Americas, … purchasing 272,139 shares in the last quarter, thus it now holds 3,049,553 shares of CRSP, with a total valuation of $158,424,278. ARK Investment Management LLC meanwhile bought more CRSP shares in the recently filed quarter, changing its stake to $153,597,188 worth of shares.
Similarly, Cormorant Asset Management LP increased its CRISPR Therapeutics AG shares by 54.90% during the recently filed quarter. After buying 1,084,300 shares in the last quarter, the firm now controls 384,300 shares of CRISPR Therapeutics AG which are valued at $56,329,385. In the same vein, Ivy Investment Management Co. increased its CRISPR Therapeutics AG shares by during the most recent reported quarter. The firm bought 44,410 shares during the quarter which increased its stakes to 1,046,328 shares and is now valued at $54,356,740. Following these latest developments, around 0.30% of CRISPR Therapeutics AG stocks are owned by institutional investors and hedge funds.